Lincoln Pharmaceuticals Ltd. Financials: Quarterly Results
Revenue
181.47
Cr.
PAT
28.60
Cr.
EBITDA
35.02
Cr.
Lincoln Pharmaceuticals Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 166.32 | 163.36 | 154.07 | 168.18 | 146.55 |
| Total Income From Operations (Cr.) | 166.32 | 163.36 | 154.07 | 168.18 | 146.55 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 35.02 | 29.04 | 35.60 | 16.61 | 29.41 |
| P/L Before Exceptional Items & Tax (Cr.) | 34.72 | 28.81 | 35.39 | 16.25 | 28.68 |
| P/L After Tax from Ordinary Activities (Cr.) | 28.60 | 19.98 | 27.68 | 11.58 | 20.77 |
| Net Profit/Loss For the Period (Cr.) | 28.60 | 19.98 | 27.68 | 11.58 | 20.77 |
| Basic EPS | 14.28 | 9.98 | 13.82 | 5.78 | 10.37 |
FAQs
Lincoln Pharmaceuticals Ltd. announced its quarterly results for Q3 FY2026 on February 12, 2026.
In Q3 FY2026, Lincoln Pharmaceuticals Ltd. are as follows:
Revenue: ₹181.47 crore
Net Profit: ₹28.60 crore.
For Q3 FY2026, Lincoln Pharmaceuticals Ltd. posted ₹181.47 crore in revenue and ₹28.60 crore in net profit.
Past quarterly results for Lincoln Pharmaceuticals Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.